Abstract:Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.See Duran-Aniotz et al. (doi 10.1093/brain/awv401) for a scientific commentary on this article.Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.The aberrant accumulation of toxic protein aggregates is a key feature of many neurodegenerative diseases, including Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease. As such, improving normal proteostatic mechanisms is an active target for biomedical research. Although they share common pathological features, protein aggregates form in different subcellular locations. N epsilon-lysine acetylation in the lumen of the endoplasmic reticulum has recently emerged as a new mechanism to regulate the induction of autophagy. The endoplasmic reticulum acetylation machinery includes AT-1/SLC33A1, a membrane transporter that translocates acetyl-CoA from the cytosol into the endoplasmic reticulum lumen, and ATase1 and ATase2, two acetyltransferases that acetylate endoplasmic reticulum cargo proteins. Here, we used a mutant form of alpha-synuclein to show that inhibition of the endoplasmic reticulum acetylation machinery specifically improves autophagy-mediated disposal of toxic protein aggregates that form within the secretory pathway, but not those that form in the cytosol. Consequently, haploinsufficiency of AT-1/SLC33A1 in the mouse rescued Alzheimer's disease, but not Huntington's disease or amyotrophic lateral sclerosis. In fact, intracellular toxic protein aggregates in Alzheimer's disease form within the secretory pathway while in Huntington's disease and amyotrophic lateral sclerosis they form in different cellular compartments. Furthermore, biochemical inhibition of ATase1 and ATase2 was also able to rescue the Alzheimer's disease phenotype in a mouse model of the disease. Specifically, we observed reduced levels of soluble amyloid-beta aggregates, reduced amyloid-beta pathology, reduced phosphorylation of tau, improved synaptic plasticity, and increased lifespan of the animals. In conclusion, our results indicate that N epsilon-lysine acetylation in the endoplasmic reticulum lumen regulates normal proteostasis of the secretory pathway; they also support therapies targeting endoplasmic reticulum acetyltransferases, ATase1 and ATase2, for a subset of chronic degenerative diseases.

α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Increased Oligomerization and Phosphorylation of Α-Synuclein Are Associated with Decreased Activity of Glucocerebrosidase and Protein Phosphatase 2A in Aging Monkey Brains

Age- and Brain Region-Dependent Α-Synuclein Oligomerization is Attributed to Alterations in Intrinsic Enzymes Regulating Α-Synuclein Phosphorylation in Aging Monkey Brains

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging

Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2

Age-dependent Aggregation of Α-Synuclein in the Nervous System of Gut-Brain Axis is Associated with Caspase-1 Activation.

Α-Synuclein: A Multifunctional Player in Exocytosis, Endocytosis, and Vesicle Recycling

Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons

Lack of α-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease

Synaptic Vesicle Depletion Correlates With Attenuated Synaptic Responses To Prolonged Repetitive Stimulation In Mice Lacking Alpha-Synuclein

Synaptojanin1 Modifies Endolysosomal Parameters in Cultured Ventral Midbrain Neurons

Altered Conformation of Α-Synuclein Drives Dysfunction of Synaptic Vesicles in a Synaptosomal Model of Parkinson's Disease.

Neurodegenerative Disease Related Proteins Have Negative Effects on SNARE-Mediated Membrane Fusion in Pathological Confirmation

Human α‐synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing

Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

Non-Motor Parkinsonian Pathology In Aging A53t Alpha-Synuclein Mice Is Associated With Progressive Synucleinopathy And Altered Enzymatic Function

α-Synuclein toxicity in yeast and human cells is caused by cell cycle re-entry and autophagy degradation of ribonucleotide reductase 1

Improved Proteostasis in the Secretory Pathway Rescues Alzheimer’s Disease in the Mouse